1.Clinical values of Optical Coherence Tomography in the diagnosis of myocardial bridge
Huaming CAO ; Jingfa JIANG ; Bing DENG
Chinese Journal of Interventional Cardiology 2003;0(06):-
Objective To investigate morphologic characteristics of myocardial bridge(MBs)in optical coherence tomography(OCT)and to investigate the relationship between MBs and atherosclerosis in the proximal segments to MBs.Methods Twelve patients(age:58.07?12.08)with MBs were examined with OCT.The location and length of the most stenosis area of MBs were observed and compared between the CAG and OCT results.The intima thickness of the proximal 2 cm arterial segment of MBs was measured.Results All the 12 MBs were found in LAD.The length of the MBs measured in OCT and CAG respecgtively was 20.5?4.2 mm vs 15.6?3.5 mm(P
2.Advances in drug therapy of diabetic retinopathy
Minghao CHEN ; Peiyu LIU ; Xuan WANG ; Yixiang WU ; Yujin JIANG ; Chaoyang ZHANG ; Jingfa ZHANG
Journal of Shanghai Jiaotong University(Medical Science) 2024;44(7):822-829
Diabetic retinopathy(DR)is one of the most common microvascular complications of diabetes and has become one of the leading causes of blindness and visual impairment in diabetes patients.The pathogenesis of DR is multifaceted,involving inflammation,oxidative stress,neurovascular abnormalities,and other factors that present potential targets for disease management interventions.Currently,anti-vascular endothelial growth factor(VEGF)drugs serve as the primary treatment for advanced stages of DR when irreversible neurovascular damage and visual impairment have occurred.Additionally,some patients show poor or no response to anti-VEGF treatment.There is a lack of early intervention options for the initial phases of the disease.Therefore,there is an urgent need to develop novel local or systemic therapies based on the underlying mechanisms of DR to enable early prevention and treatment with the aim of preserving patients' vision.Medications targeting various pathways including anti-inflammatory agents(corticosteroids and nonsteroidal anti-inflammatory drugs),neurotrophic and neuroprotective drugs,drugs modulating biochemical pathways,antioxidant phytochemicals,and gene therapy can complement each other in terms of therapeutic effects to benefit a larger number of individuals affected by DR.This article reviews previous research reports on the pathogenesis,drug treatment methods,and potential therapeutic targets associated with DR in order to provide guidance for clinical practice.
3.The Global Landscape of SARS-CoV-2 Genomes, Variants, and Haplotypes in 2019nCoVR
Song SHUHUI ; Ma LINA ; Zou DONG ; Tian DONGMEI ; Li CUIPING ; Zhu JUNWEI ; Chen MEILI ; Wang ANKE ; Ma YINGKE ; Li MENGWEI ; Teng XUFEI ; Cui YING ; Duan GUANGYA ; Zhang MOCHEN ; Jin TONG ; Shi CHENGMIN ; Du ZHENGLIN ; Zhang YADONG ; Liu CHUANDONG ; Li RUJIAO ; Zeng JINGYAO ; Hao LILI ; Jiang SHUAI ; Chen HUA ; Han DALI ; Xiao JINGFA ; Zhang ZHANG ; Zhao WENMING ; Xue YONGBIAO ; Bao YIMING
Genomics, Proteomics & Bioinformatics 2020;18(6):749-759
On January 22, 2020, China National Center for Bioinformation (CNCB) released the 2019 Novel Coronavirus Resource (2019nCoVR), an open-access information resource for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2019nCoVR features a comprehensive integra-tion of sequence and clinical information for all publicly available SARS-CoV-2 isolates, which are manually curated with value-added annotations and quality evaluated by an automated in-house pipeline. Of particular note, 2019nCoVR offers systematic analyses to generate a dynamic landscape of SARS-CoV-2 genomic variations at a global scale. It provides all identified variants and their detailed statistics for each virus isolate, and congregates the quality score, functional annotation,and population frequency for each variant. Spatiotemporal change for each variant can be visualized and historical viral haplotype network maps for the course of the outbreak are also generated based on all complete and high-quality genomes available. Moreover, 2019nCoVR provides a full collection of SARS-CoV-2 relevant literature on the coronavirus disease 2019 (COVID-19), including published papers from PubMed as well as preprints from services such as bioRxiv and medRxiv through Europe PMC. Furthermore, by linking with relevant databases in CNCB, 2019nCoVR offers data submission services for raw sequence reads and assembled genomes, and data sharing with NCBI. Collectively, SARS-CoV-2 is updated daily to collect the latest information on genome sequences, variants, hap-lotypes, and literature for a timely reflection, making 2019nCoVR a valuable resource for the global research community. 2019nCoVR is accessible at https://bigd.big.ac.cn/ncov/.